Efficacy and Safety With Ziprasidone in the Treatment of First-episode Schizophrenia Spectrum Disorder: Multi-center Study

Chonbuk National University Hospital6 个研究点分布在 2 个国家目标入组 27 人开始时间: 2010年7月7日最近更新: 2010年7月7日

适应症

试验速览

阶段: 4 期
状态: 已完成
发起方: Chonbuk National University Hospital
入组人数: 27
试验地点: 6
主要终点: Symptoms assessment by objective rating scales

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The aim of the study is to investigate the efficacy and safety of ziprasidone in patients with first episode psychosis.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Single Group
主要目的: Treatment
盲法: None

入排标准

年龄范围: 14 Years 至 45 Years（Child, Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients who meet DSM-IV criteria for first episode schizophrenia, schizophreniform disorder and schizoaffective disorder

排除标准

•Patients with previously prescribed antipsychotic medication in 2 weeks or more
•patients with substance-induced psychotic disorder, serious suicide attempt, neurological disorder, etc.

结局指标

主要结局

Symptoms assessment by objective rating scales

时间窗: week 8

PANSS total score, SANS, clinical global impression scale, GAF, DAS-S

次要结局

Assessment of adverse events by objective rating scales and self report scales(two-month.)

研究者

发起方

Chonbuk National University Hospital

申办方类型

Other

研究点 (6)

Loading locations...

相似试验

终止

3 期

Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I DisorderBipolar Disorder

NCT02075047Pfizer's Upjohn has merged with Mylan to form Viatris Inc.171

终止

3 期

Safety And Efficacy Of Ziprasidone In Adolescents With SchizophreniaSchizophrenia

NCT00257192Pfizer's Upjohn has merged with Mylan to form Viatris Inc.284

已完成

4 期

Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar DisorderBipolar DisorderMania

NCT00181922Massachusetts General Hospital20

已完成

4 期

Effectiveness of Ziprasidone for Patients With SchizophreniaSchizophreniaSchizoaffective Disorder

NCT01198353Soonchunhyang University Hospital67

Unknown

不适用

Efficacy and Safety of Ziprasidone to Treat Depressive Symptoms in Patients With SchizophreniaThe Primary Evaluation is the Change From Baseline at End of Study for CDSS Total Scores.The Secondary Efficacy Evaluations Include: MADRS, PANSS Total Scores and Subscales and Responder Rate; CGI-S and CGI-I Scales.Safety Evaluations Include: Laboratory Test Abnormalities; BARS and SAS; Physical Examinations; Vital Signs; Electrocardiogram,Etc.Subjective Well-being Under Neuroleptics Short Form Will be Used in Our Study to Assess the Subjective Side-effects.

NCT01260116Wuhan University120